Progesterone receptors, in breast cancer

Press MF, Spaulding B, Groshen S, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 2002 67 799-813. 

Cavaliere A, BucciareUi E, Sidoni A, Bianchi G, Pietropaoli N, et al. Estrogen and progesterone receptors in breast cancer Comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay. Cytometry 1996 26 204-08. 

Masood S, Dee S, Goldstein JD. Immunocytochemical analysis of progesterone receptors in breast cancer. Am J Clin Pathol. 1991 96 59-63. 

There is little doubt that the presence of estrogen and progesterone receptors in breast cancer tissue correlates very well with the response of the patient to endocrine therapy. ERP/progesterone receptor protein (PRP) measurements have... 

G3. Greene, G. L., and Press, M. F., Immunochemical evaluation of estrogen receptor and progesterone receptor in breast cancer. In Immunological Approaches to the Diagnosis and Therapy of Breast Cancer (R. Ceriani, ed.), pp. 119-135. Plenum, New York, 1987. 

L5. Loven, D., Rakowsky, E., Geier, A., Lunenfeld, B., Rubinstein, A., Klein, B., and Lurie, H., A clinical evaluation of nuclear estrogen receptors combined with cytosolic estrogen and progesterone receptors in breast cancer. Cancer (Philadelphia) 66, 341-346 (1990). 

S. G., Progression free interval in primary additive hormonal therapy in metastatic breast cancer related to estrogen and progesterone receptor levels. Breast Cancer Res. Treat. 8(1), 107 (1986). 

L2. Lesser, M., Rosen, P. P., Senie R., Duthie, K., Menendez-Botet, C. J., and Schwartz, M. K., Estrogen and progesterone receptors in breast carcinoma. Correlations with epidemiology and pathology. Cancer (Philadelphia) 48, 299-309 (1981). 

Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4 197... 

Ozello, L., DeRosa, C., Habif, D. V., and Greene, G. L. (1991) An immunohis-tochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer 67,455 62. 

Biesterfeld, S., Veuskens, U., Schmitz, F.-J., Amo-Takyi, B., and Bocking, A. 1996. Interobserver reproducibility of immunocytochemical estrogen and progesterone receptor status assesment in breast cancer. Anticancer Res. 76 2497-2500. 

Mote, P. A., Leary, J. A., and Clarke, C. L. 1997. Immunohistochemical detection of progesterone receptors in archival breast cancer. Biotech. Histochem. 73 117-127. 

Perrot-Applanat, M., Groyer-Picard, M.-T., Vu Hai, M. T., Pallud, C., Spyratos, F., and Milgrom, E. 1989. Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers. Am. J. Pathol. 735 457-468. 

Fuqua, S.A. and Cui, Y. 2004. Estrogen and progesterone receptor isoforms Clinical significance in breast cancer. Breast Cancer Res. Treat. 87(Suppl. 1), S3-S10. 

Most steroid-sensitive cancers express specific cell surface receptors. Prednisone-sensitive lymphomas, estrogen-sensitive breast cancers, and prostatic cancers express specific receptors for corticosteroids, estrogens, and androgens, respectively. It is now possible to assay tumor specimens for steroid receptor content and to identify which individual patients are likely to benefit from hormonal therapy. Measurement of the estrogen receptor (ER) and progesterone receptor (PR) proteins in breast cancer tissue is now standard clinical practice. ER or PR positivity predicts response to hormonal therapy, whereas patients whose tumors are ER-negative generally fail to respond to such treatment. 

Most hormone-sensitive cancers will express hormone receptors that can be assayed on biopsy specimens. This allows the clinician to predict whether an individual patient is likely to benefit from hormonal therapy. For example, it is now standard to measure estrogen receptor (ER) and progesterone receptor (PR) content in breast cancer tissue. Patients with ER- or PR-positive tumors are more likely to respond to antiestrogen therapy compared with patients who lack these hormone receptors. 

Estrogen and progesterone receptors are used in breast cancer as indicators for hormonal therapy. ° Patients with positive estrogen and progesterone receptors tend to respond to hormonal treatment. Those with negative receptors will be treated using other therapies, such as chemotherapy. 

Jarque F, Lluch A, Vizcarra E, Munoz M, Alberola V, Garca-Conde J. Quantitative monoclonal antibody determination of estrogen and progesterone receptors in human breast cancer Correlation with the radioligand method. Oncology 1994 51 435-39. 

---